bxpc-3 tumor model  (Kisker Biotech)

Journal: International journal of pharmaceutics

Article Title: In vivo preclinical evaluation of the new 68 Ga-labeled beta-cyclodextrin in prostaglandin E2 (PGE2) positive tumor model using positron emission tomography.

doi: 10.1016/j.ijpharm.2019.118954

Figure Lengend Snippet: Fig. 4. In vivo dynamic miniPET imaging of BxPC3 tumor-bearing SCID mice after intravenous injection of 68Ga-NODAGA-RAMEB (A, B) and 68Ga-NODAGA- RAMEB + 1 mg PGE2 (C, D). Representative time dependent decay-corrected coronal and axial miniPET images of BxPC3 tumor-bearing SCID mouse in the absence (A) and presence of PGE2 (C). Time-activity curve (TAC) analysis of 68Ga-NODAGA-RAMEB (B) and 68Ga-NODAGA-RAMEB + 1 mg PGE2 (D) accumulation in experimental PGE2 positive BxPC3 tumors. PET images and data were obtained 12 ± 1 days after tumor cell inoculation. Red arrows: BxPC3 tumors. SUV: standardized uptake value; T/M: tumor-to-muscle ratio (SUVmean). SUV values are presented as mean ± SD. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: For the induction of tumor models BxPC3 (ATCC, CRL-168) or PancTu-1 (kind gift from the University of Hamburg) human pancreas adenocarcinoma cells were injected (5 × 106 cells in 100 μL 0.9% NaCl) subcutaneously into the left shoulder area of CB17 SCID mice.

Techniques: In Vivo, Imaging, Injection, Activity Assay

Journal: International journal of pharmaceutics

Article Title: In vivo preclinical evaluation of the new 68 Ga-labeled beta-cyclodextrin in prostaglandin E2 (PGE2) positive tumor model using positron emission tomography.

doi: 10.1016/j.ijpharm.2019.118954

Figure Lengend Snippet: Fig. 5. In vivo assessment of 68Ga-NODAGA-RAMEB accumulation of human pancreas adenocarcinoma cells using miniPET imaging. A: Representative decay-corrected coronal and axial miniPET images of BxPC3 (left) and PancTu- 1 (right) tumor-bearing SCID mice 80–90 min after intravenous injection of 68Ga-NODAGA-RAMEB. B: Quantitative SUV analysis of 68Ga-NODAGA-RAMEB uptake in experimental tumors 80–90 min after intravenous injection of the radiotracer. PET images and data were obtained 12 ± 1 days after tumor cell inoculation. Red arrows: BxPC3 tumors; black arrows: PancTu-1 tumors. SUV: standardized uptake value; T/M: tumor-to-muscle ratio (SUVmean and SUVmax). Significance level: p ≤0.01 (*). SUV values are presented as mean ± SD. (For interpretation of the references to colour in this figure le- gend, the reader is referred to the web version of this article.)

Article Snippet: For the induction of tumor models BxPC3 (ATCC, CRL-168) or PancTu-1 (kind gift from the University of Hamburg) human pancreas adenocarcinoma cells were injected (5 × 106 cells in 100 μL 0.9% NaCl) subcutaneously into the left shoulder area of CB17 SCID mice.

Techniques: In Vivo, Imaging, Injection

Journal: International journal of pharmaceutics

Article Title: In vivo preclinical evaluation of the new 68 Ga-labeled beta-cyclodextrin in prostaglandin E2 (PGE2) positive tumor model using positron emission tomography.

doi: 10.1016/j.ijpharm.2019.118954

Figure Lengend Snippet: Fig. 6. Ex vivo evaluation of 68Ga-NODAGA-RAMEB accumulation in PGE2 positive BxPC3 tumor-bearing CB17 SCID mice (n = 15) 30, 60 and 90 min after intravenous injection of the radiotracer and 12 ± 1 days after tumor cell inoculation. Significance level between 30 and 90 min: p ≤0.01 (*). %ID/g values are presented as mean ± SD.

Article Snippet: For the induction of tumor models BxPC3 (ATCC, CRL-168) or PancTu-1 (kind gift from the University of Hamburg) human pancreas adenocarcinoma cells were injected (5 × 106 cells in 100 μL 0.9% NaCl) subcutaneously into the left shoulder area of CB17 SCID mice.

Techniques: Ex Vivo, Injection

Journal: International journal of pharmaceutics

Article Title: In vivo preclinical evaluation of the new 68 Ga-labeled beta-cyclodextrin in prostaglandin E2 (PGE2) positive tumor model using positron emission tomography.

doi: 10.1016/j.ijpharm.2019.118954

Figure Lengend Snippet: Fig. 7. Histological analysis of subcutaneously growing BxPC3 (A and B panel) and PancTu-1 (C and D panel) tumors 11 days after tumor cell in- oculation. A and C: Representative hematoxylin- eosin stained tumor tissue; B and D: Anti- Prostaglandin E Receptor EP2/PTGER2 antibody immunohistochemistry (IHC), visualized with 3,3-diaminobenzidine (DAB) (brown staining). Magnification: 40X.

Article Snippet: For the induction of tumor models BxPC3 (ATCC, CRL-168) or PancTu-1 (kind gift from the University of Hamburg) human pancreas adenocarcinoma cells were injected (5 × 106 cells in 100 μL 0.9% NaCl) subcutaneously into the left shoulder area of CB17 SCID mice.

Techniques: Staining, Immunohistochemistry

Journal: Molecular cancer research : MCR

Article Title: Combined Src/EGFR inhibition targets STAT3 signaling and induces stromal remodeling to improve survival in pancreatic cancer

doi: 10.1158/1541-7786.MCR-19-0741

Figure Lengend Snippet: Combined Src and EGFR inhibition decreases tumor collagen content and reduces fibrosis in an orthotopic mouse model of PDAC. Orthotopic BxPC3 (A) and PANC1 (B) tumor xenografts were established in nude mice (n=5 per group) and treated with vehicle, dasatinib (DST, 25 mg/kg/daily), erolitinib (ERL, 50 mg/kg/daily), and/or gemcitabine (GEM, 15 mg/kg/every three days) for three weeks prior to sacrifice. IHC was performed for collagen IV and trichrome blue staining in xenograft tumor samples. Representative collagen IV and trichrome blue staining of BxPC3 (A, top panels) and PANC1 (B, top panels) xenograft tissues were shown (scale bar = 50 μm). Expression levels of collagen IV and trichrome blue were quantified using Image J from BxPC3 (A, lower panels) and PANC1 (B, lower panels) xenograft tissues and reported as percentage positive staining of total area. ns, nonsignificant; **, p<0.01; ***, p<0.001; ****, p<0.0001.

Article Snippet: Cell Lines and orthotopic tumor models Human pancreatic cancer cell lines BxPC3 and PANC1 were obtained from American Type Culture Collection (ATCC) and maintained according to the ATCC guidelines.

Techniques: Inhibition, Staining, Expressing

Journal: Molecular cancer research : MCR

Article Title: Combined Src/EGFR inhibition targets STAT3 signaling and induces stromal remodeling to improve survival in pancreatic cancer

doi: 10.1158/1541-7786.MCR-19-0741

Figure Lengend Snippet: Combined Src and EGFR inhibition decreases STAT3 activity and enhances microvessel density in an orthotopic mouse model of PDAC. Histologic analysis was performed for pSTAT3 (A) and CD31 (B) in vehicle, dasatinib (DST, 25 mg/kg/daily), erolitinib (ERL, 50 mg/kg/daily), and/or gemcitabine (GEM, 15 mg/kg/every three days) treated BxPC3 orthotopic tumor xenograft samples (n=3–5 per group, scale bar = 50 μm). pSTAT3 (A) and CD31 (B) positive expression levels were analyzed and reported as percentage positive staining of total area. ns, nonsignificant; *, p<0.05; ***, p<0.001; ****, p<0.0001.

Article Snippet: Cell Lines and orthotopic tumor models Human pancreatic cancer cell lines BxPC3 and PANC1 were obtained from American Type Culture Collection (ATCC) and maintained according to the ATCC guidelines.

Techniques: Inhibition, Activity Assay, Expressing, Staining